The global intermediate age-related macular degeneration market is poised for significant growth, driven by the rising aging population and increased ...

Both anti-VEGF and surgical treatments improve VA in AMD-related submacular hemorrhage, with no statistically significant difference between the two treatments. Anti-VEGF injections may be ...

EYP-1901 shows promising results in reducing treatment burden for diabetic macular edema, offering sustained improvements in ...

D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment ...

Diabetes is a leading cause of vision loss in the United States, and cataracts are a common complication of the disease. With ...

These interim results support MGB’s potential in decreasing the need for supplemental intravitreal injections of anti-VEGF, suggesting a potential new treatment pathway for patients.

To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ophthalmology over the past five decades.

Cataract surgery is the most commonly performed eye surgery in the ophthalmology, with a track record of improving vision and ...

Combination therapy shows promise in improving outcomes and reducing the treatment burden associated with frequent anti-VEGF injections.

This article evaluates the currently used treatment regimens in ocular anti-VEGF therapy for exudative age-related macular degeneration. Anti-VEGF therapies using variable injection regimens and ...

This strategy may reduce the number of anti-VEGF injections required and, subsequently, risks, inconvenience, and costs to people and health care services.